My WebLink
|
Help
|
About
|
Sign Out
Home
Browse
Search
2025-223
CBCC
>
Official Documents
>
2020's
>
2025
>
2025-223
Metadata
Thumbnails
Annotations
Entry Properties
Last modified
10/27/2025 12:29:35 PM
Creation date
10/27/2025 12:28:42 PM
Metadata
Fields
Template:
Official Documents
Official Document Type
Settlement Agreement
Approved Date
10/07/2025
Control Number
2025-223
Agenda Item Number
9.U.
Entity Name
Alvogen, Amneal, Apotex, Hikma, Indivior, Mylan, Sun and Zydus
Subject
Secondary Manufacturers Settlements Participation and Release form
There are no annotations on this page.
Document management portal powered by Laserfiche WebLink 9 © 1998-2015
Laserfiche.
All rights reserved.
/
7
PDF
Print
Pages to print
Enter page numbers and/or page ranges separated by commas. For example, 1,3,5-12.
After downloading, print the document using a PDF reader (e.g. Adobe Reader).
View images
View plain text
Docusign Envelope ID: A89F5B7A-EA41-4585-AE34-A3E2A4104705 <br />reference ID of your subdivision in the body of the email and use the subject <br />line Combined Settlement Participation Form - [Subdivision Name, Subdivision <br />State] - [Reference ID]. <br />Detailed instructions on how to sign and return the Combined Participation Form, <br />including changing the authorized signer, can be found at <br />htti)s://nationaloi)ioidsettlement.com/additional-settlements/. You may also contact <br />opioidsparticipation@rubris.com. <br />The sign -on period for subdivisions ends on October 8, 2025. <br />If you have any questions about executing the Combined Participation Form, please <br />contact your counsel or the Implementation Administrator at <br />opioidsparticipation(a)rubris.com. <br />Thank you, <br />Secondary Manufacturers Settlements Implementation Administrator <br />The Implementation Administrator is retained to provide the settlement notice <br />required by the Secondary Manufacturers Settlements and to manage the collection <br />of the Combined Participation Form. <br />
The URL can be used to link to this page
Your browser does not support the video tag.